Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Murano Global Investments Plc (MRNO) is up 146% at $3.35 [3] - Kustom Entertainment, Inc. (KUST) is up 34% at $2.84 [3] - Ainos, Inc. (AIMD) is up 34% at $2.32 [3] - Stride, Inc. (LRN) is up 29% at $94.10 [3] - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is up 18% at $2.40 [3] - Battalion Oil Corporation (BATL) is up 16% at $3.83 [3] - C3.ai, Inc. (AI) is up 15% at $14.58 [3] - Lantronix, Inc. (LTRX) is up 14% at $7.87 [3] - Nextpower Inc. (NXT) is up 13% at $120.00 [3] - High Roller Technologies, Inc. (ROLR) is up 7% at $7.56 [3] Premarket Losers - Flora Growth Corp. (FLGC) is down 34% at $7.20 [4] - TEN Holdings, Inc. (XHLD) is down 29% at $2.47 [4] - Global Interactive Technologies, Inc. (GITS) is down 22% at $3.25 [4] - 5E Advanced Materials, Inc. (FEAM) is down 15% at $2.70 [4] - Vyome Holdings, Inc. (HIND) is down 14% at $2.79 [4] - Altimmune, Inc. (ALT) is down 11% at $5.48 [4] - BiomX Inc. (PHGE) is down 10% at $6.22 [4] - Qorvo, Inc. (QRVO) is down 9% at $74.94 [4] - Nuwellis, Inc. (NUWE) is down 9% at $3.45 [4] - Brenmiller Energy Ltd (BNRG) is down 9% at $2.90 [4]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 500 points, down 1.18% to 48,776.25, as President Trump's tariff threats over the Greenland dispute affected global markets [1] - The NASDAQ dipped 1.54% to 23,152.09, and the S&P 500 fell 1.22% to 6,855.01 [1] Sector Performance - Energy shares gained by 0.6% on Tuesday, while consumer discretionary stocks dipped by 2% [2] Company Earnings - 3M Company reported fourth-quarter 2025 adjusted sales of $6.023 billion, slightly above the consensus estimate of $6.012 billion, with a year-on-year increase of 3.7% [3] - Adjusted organic sales for 3M rose 2.2% year-on-year, and adjusted earnings per share increased 9% year-on-year to $1.83, surpassing the Street estimate of $1.80 [3] Commodities - Oil traded up 1.6% to $60.40, gold increased by 3.3% to $4,745.30, silver rose 7% to $94.70, while copper fell 0.7% to $5.7900 [6] European Market Performance - European shares were lower, with the eurozone's STOXX 600 falling 1%, Spain's IBEX 35 Index down 1.5%, London's FTSE 100 dipping 1%, Germany's DAX falling 1.2%, and France's CAC 40 slipping 1% [7] Asian Market Performance - Asian markets closed mostly lower, with Japan's Nikkei falling 1.11%, Hong Kong's Hang Seng Index declining 0.29%, China's Shanghai Composite down 0.01%, and India's BSE Sensex falling 1.28% [10] Notable Stock Movements - INVO Fertility Inc shares surged 361% to $3.75 amid rumors of potential government support for fertility treatments [9] - Shuttle Pharmaceuticals Holdings Inc shares increased by 146% to $4.01, while Top Wealth Group Holding Ltd shares rose 114% to $7.45 following an acquisition announcement [9] - Venus Concept Inc shares dropped 41% to $4.73 after a significant previous increase, and NovaBay Pharmaceuticals Inc shares fell 39% to $9.05 after filing for a stock offering [9]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]

Core Insights - LexinFintech Holdings Ltd reported a significant increase in quarterly earnings, reaching 43 cents per share, compared to 28 cents per share in the same quarter last year [1] - The company's sales for the quarter were $367.580 million, a decrease from $521.851 million in the previous year [1] - Following the earnings report, LexinFintech shares surged by 15.3% to $4.03 in pre-market trading [1] Company Performance - LexinFintech's earnings per share increased by 53.6% year-over-year [1] - The decline in sales represents a year-over-year decrease of approximately 29.4% [1] - The positive market reaction indicates investor confidence despite the drop in sales [1]

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has filed a provisional patent application for "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy," which is a significant step in advancing its diagnostic and therapeutic programs for prostate cancer [1][7]. Company Overview - Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company founded in 2012, focused on improving outcomes for cancer patients treated with radiation therapy [8]. - The company aims to develop therapies that maximize the effectiveness of radiation therapy while minimizing side effects, thereby improving cancer cure rates and patient quality of life [8]. Research and Development - The provisional patent application is part of the company's efforts to create highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, utilizing PSMA ligands for accurate imaging and targeted therapy delivery [1][7]. - The collaboration with Dr. Alan Kozikowski, a pioneer in PSMA targeting, has been instrumental in the development of these therapeutic agents [2][5]. Market Potential - The global PSMA PET imaging market was valued at $1.5 billion in 2022 and is projected to reach $2.0 billion by 2030, indicating significant growth potential in this area [7]. - The targeted radiopharmaceutical treatment Pluvitco® for PSMA-positive metastatic prostate cancer is expected to have a market size of $2 billion [7]. Diagnostic Initiatives - Shuttle Diagnostics, a subsidiary of Shuttle Pharmaceuticals, is focused on developing pretreatment diagnostic blood tests for prostate cancer patients, including the PSMA-B ligand and the PC-Rad test [4]. - Currently, there are no available tests on the market that can predict treatment success for prostate cancer specifically [4]. Scientific Collaboration - The company has collaborated with Dr. Kozikowski and other researchers to discover novel PSMA ligands aimed at enhancing the targeting of prostate cancer cells [5][6]. - The research into antibody-drug conjugates (ADCs) and the advantages of smaller PSMA targeting ligands for drug delivery is a promising area of exploration [3].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a public offering of 19,166,667 shares at a price of $0.30 per share, raising approximately $5.75 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering consisted of common stock and pre-funded warrants, with the total gross proceeds amounting to about $5.75 million [1]. - The offering was conducted on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund a Phase II clinical trial for the company's lead product candidate, as well as for marketing, advertising services, working capital, and general corporate purposes [2]. Group 3: Company Background - Shuttle Pharmaceuticals, founded in 2012 by faculty members of Georgetown University Medical Center, focuses on improving outcomes for cancer patients undergoing radiation therapy [5]. - The company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates and improve patient quality of life [5].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a public offering of 19,166,667 shares at a price of $0.30 per share, aiming to raise approximately $5.75 million to fund its Phase II clinical trial and other corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at $0.30 per share, with expected gross proceeds of about $5.75 million before expenses [1]. - The offering is set to close on March 13, 2025, pending customary closing conditions [1]. - WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund the Phase II clinical trial for the lead product candidate, marketing and advertising services, and general corporate purposes [2]. Group 3: Company Overview - Shuttle Pharmaceuticals, founded in 2012, focuses on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [5]. - The company aims to increase cancer cure rates and improve patient quality of life through the development of radiation sensitizers [5].

Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has appointed Christopher Cooper as interim Co-Chief Executive Officer to enhance capital markets and business capabilities [1][2] - Dr. Anatoly Dritschilo will continue as Co-CEO, focusing on scientific and clinical trial activities [1][2] - The dual CEO structure aims to improve decision-making, support fundraising, and accelerate key milestones [2] Company Overview - Shuttle Pharmaceuticals, founded in 2012, is a specialty pharmaceutical company focused on improving outcomes for cancer patients undergoing radiation therapy [3] - The company's mission is to develop therapies that maximize the effectiveness of radiation therapy while minimizing side effects [3] - Shuttle Pharma aims to increase cancer cure rates, prolong survival, and improve quality of life through the development of radiation sensitizers [3] Leadership Background - Christopher Cooper has over 27 years of experience in management and finance across various industries, including telecommunications and oil and gas [2] - He has held significant positions such as President and CEO of First Towers & Fiber Corp. and Aroway Energy, Inc. [2] - Cooper has a proven track record in overseeing operations, financial reporting, and raising over $100 million in debt and equity for clients [2]